Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark inks agreement SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Posted On: 2021-08-02 03:29:10 (Time Zone: UTC)


Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company and Canadian biotech firm SaNOtize Research & Development Corp. today announced an exclusive long term strategic partnership to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.

In March 2021, SaNOtize's clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms. In the first 24 hours, NONS reduced the average viral load by around 95%, and then by more than 99% within 72 hours. It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.

Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide (NO), a natural nano-molecule with proven anti-microbial properties, and which has a direct effect on SARS-CoV-2, the virus causing COVID-19.

In early July 2021, Glenmark presented a proposal to the Subject Expert Committee of CDSCO for emergency approval for import and marketing of the nasal spray. The committee has recommended a Phase III clinical trial to be conducted in Indian patients in the weeks to follow. The Phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand name FabiSpray® in India, by fourth quarter of the calendar year 2021.

"Our efforts since the beginning of COVID-19 have been to provide patients with safe and effective treatment options to fight the disease. This partnership with SaNOtize closely aligns with Glenmark's focused approach against COVID-19 and will help reduce the burden of the pandemic in the region." said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd. He further added, "It also marks another valuable in-licensing opportunity for us in our key therapy area of respiratory medicine, as well as the possibility to globally supply the product to SaNOtize and its partners outside of our territory. Glenmark will ensure timely and widespread access to this effective nasal spray, which we hope will bring much needed relief to patients across the region and the wider world."

"COVID-19 and its various variants are proving to be a challenge to contain despite the rapid - and critical - development of vaccines," said Dr. Gilly Regev, CEO & Co-founder of SaNOtize. "SaNOtize is excited to collaborate with Glenmark in providing broader, easier and affordable access to its treatment. In joining forces with Glenmark, SaNOtize can accelerate the efforts to have its antiviral nasal spray available as a self-administered, first line of defence against COVID-19 during the current pandemic and to help prevent future outbreaks."

NONS is one of the few novel therapeutic treatments, outside of expensive monoclonal antibodies, that is proven to reduce SARS-CoV-2 viral load in humans.2 NONS has already received a CE mark in Europe, which is an equivalent of marketing authorization in case of a Medical Device (CE mark confirms that the medical device meets certain "essential requirements" of the European General Medical Devices Directive and is safe for the intended purpose). By virtue of the CE mark, SaNOtize has permission to launch NONS in the EU. NONS is also approved and being sold in Israel and Bahrain, under the name enovid™.

SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections in 2017. Glenmark's partnership with SaNOtize will bring in much needed therapeutic relief to patients in India and Asia.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs. 607.6 as compared to the previous close of Rs. 591.6. The total number of shares traded during the day was 120207 in over 4308 trades.

The stock hit an intraday high of Rs. 611.65 and intraday low of 590.7. The net turnover during the day was Rs. 72429104.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

MTAR Technologies Ltd receives NADCAP certification for 100% EOU unit

RattanIndia Enterprises launches drones business in wholly owned subsidiary NeoSky India Limited

Hero MotoCorp recognized by Guinness World Record

Surya Roshni Ltd receives order of Rs. 41.22 crore

Narbada Gems and Jewellery Ltd approves renewal of working capital facilities

Gyscoal Alloys Ltd updates on rights issue

Archit Organosys Ltd to expand capacity by 6000 MT per annum

Rajnish Wellness Ltd announces Dava Discount Business Model

KEC International wins New Orders of Rs. 1,157 crores

Torrent Power acquires 156 MW Wind Power Plants from CESC Limited

Rajratan Global Wire Limited receives investment promotion assistance of Rs. 2.82 crore

TCS Recognized as a Leader in ACES Automotive Engineering Services by Everest Group

Deep Energy Resources Ltd arm selected as CBM developer for Jharia CBM Block-I

Infosys Collaborates with ServiceNow to Provide Enterprise-Level Service Management for Manufacturing Customers

₹ 200 Crore Base Issue Size of Public Issue of NCDs by Indiabulls Housing Finance Limited Oversubscribed 4.04x Times

Steel Strips Wheels Limited receives approval for resolution plan for AMW Autocomponent Ltd

KIOCL Ltd shuts down pellet plant

Garware Hi-Tech Films Ltd Bags Silver at India Green Manufacturing Challenge Award 2020-21

HCL Technologies and Lendico, an ING Germany Company, Join Forces in Building Solutions for SMEs

Happiest Minds wins two awards at Asiamoney Asia's Outstanding Companies Poll 2021

Chalet Hotels Ltd. becomes first hospitality company globally to join Climate Group's RE100, EP100 and EV100 initiatives

Atishay Limited appointed partner for Providing Door to Door Public Service Delivery to the Citizens

Lincoln Pharmaceuticals Ltd acquires a plant in Mehsana, Gujarat, plans to launch Cephalosporin products soon

Tata Motors to increase prices of its commercial vehicles from 1st October 2021

Cyient Joins TM Forum to collaborate with global CSPs to drive digital transformation in the Communications industry

BLS International selected as National Business Correspondent for India's largest bank, State Bank of India

Clean Science and Technology Ltd to acquire immovable property for Rs. 32.01 crores

Godrej Industries Ltd to issue NCDs for Rs. 750 crore

HDFC announces festive home loan offer with rates at 6.70%

Fineotex Products now ECO PASSPORT certified by OEKO-TEX®, audit conducted by Hohenstein, Germany

L&T Hydrocarbon Engineering bags significant orders from GAIL, Air Products Middle East Industrial Gases LLC

Hon'ble High Court of Delhi passes an order in favour of EaseMyTrip regarding unsolicited messages

Sterling and Wilson Solar Limited commissions 66 MWp solar energy project in Jordan

RattanIndia Enterprises appoints Mr. Peeyush Kumar as Head for their Drone business

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%

PDS Multinational Fashions Limited appoints Raamann Ahuja as Group Chief Human Resources Officer

Mr. Sumit Kumar Shaw resigns from Websol Energy System Ltd

K P Energy Ltd receives LOI aggregating Rs. 119.73 crores

Gensol Engineering Ltd acquires 51.68% stake in Solarig Gensol Utilities Pvt Ltd

Action Construction Equipment Ltd fixes floor price for QIP as Rs. 254.55

HCL Technologies to Drive Digital Speed, Transformation for MKS Instruments

Choice International Ltd secures IRDAI nod for stake acquisition

SoftSol India Limited to consider loan of $5 mn to subsidiary

Firstsource awarded IIP 'We invest in people' Gold accreditation for the second time in a row

TCS' Quartz™ Named a Leading Crypto Player in Transaction Banking and Payments by Celent

Ind-Ra revises outlook on IVP Limited

Apollo Tricoat Tubes Ltd board allots 3,04,00,000 bonus equity shares

Indian Sucrose Ltd board approves expansion projects

R & B Denims Limited to participate in Cairo Fashion & Tex Fair, 2021

Zydus Healthcare Limited to sell two brands Mifegest and Cytolog


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020